The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52.
- Author:
Ji-dong JIA
1
;
Jin-lin HOU
;
You-kuan YIN
;
Dao-zhen XU
;
De-ming TAN
;
Jun-qi NIU
;
Xia-qiu ZHOU
;
Yu-ming WANG
;
Li-min ZHU
;
Yong-wen HE
;
Hong REN
;
Mo-bin WAN
;
Cheng-wei CHEN
;
Shan-ming WU
;
Ya-gang CHEN
;
Jia-zhang XU
;
Qin-huan WANG
;
Lai WEI
;
Hong MA
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antiviral Agents; therapeutic use; DNA, Viral; blood; Double-Blind Method; Female; Hepatitis B, Chronic; drug therapy; Humans; Lamivudine; therapeutic use; Male; Middle Aged; Nucleosides; therapeutic use; Pyrimidinones; therapeutic use; Thymidine; analogs & derivatives; Treatment Outcome; Young Adult
- From: Chinese Journal of Hepatology 2007;15(5):342-345
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo investigate the possibilities of an association between the degrees of HBV suppression with nucleoside treatments at week 24 and week 52 in hepatitis B patients and to find a useful predictor for treatment efficacy.
METHODSIn this phase III, double-blind, multicenter trial, we compared the efficacy of telbivudine treatment with lamivudine treatment in 332 Chinese compensated chronic hepatitis B patients. The patients were randomly assigned to a daily 600 mg telbivudine treatment group or daily 100 mg lamivudine group for 24 weeks. They were then categorized into 4 groups according to their serum HBV DNA levels (copies/ml) at week 24: a PCR-undetectable group (< 300 copies/ml); a QL- < 10(3) copies/ml group; a 10(3)-<10(4) copies/ml group; and a > or = 10(4) copies/ml group. The treatments were continued as they previously had been for another 28 weeks and the patients serum HBV DNA levels were examined again.
RESULTSAt week 52, mean reductions of serum HBV DNA were significantly greater in the telbivudine-treated patients than in the lamivudine-treated group (6.2 log10 vs 5.4 log10, t = 3.6, P < 0.01). Viral resistance was twice as common in lamivudine-treated patients compared to those receiving telbivudine. Telbivudine was well-tolerated with an adverse event profile similar to that of lamivudine. The lower the HBV DNA level achieved at week 24, the higher HBV DNA non-detectable by PCR. ALT normalization and HBeAg seroconversion achieved at week 52, and viral resistance at week 48 decreased parallel to the degree of HBV DNA inhibition.
CONCLUSIONHBV DNA PCR-undetectable at week 24 in nucleoside-treated hepatitis B patients suggests a better efficacy at week 52 and lower viral resistance at week 48. The degree of suppression of HBV at week 24 may be used as a predictor of 1-year outcome.